August 9, 2022

Landmark 14-Site Study Demonstrates MicroGenDX Next-Generation Sequencing (NGS) Provides More Comprehensive Diagnosis of Periprosthetic Joint Infection

Largest study of its kind evaluates present and future role of NGS in orthopedic infections.
June 14, 2022

MicroGenDX Provides Rapid Screening for Candida Auris to Help Avoid Outbreaks in Healthcare Settings

Candida auris causes serious infections, and cases are rising across the U.S…..MicroGenDX testing also facilitates the rapid intervention and precautions needed to prevent outbreaks in healthcare settings by returning results within 24-48 hours.
June 6, 2022

Multiple Studies Validate Growing Role Molecular Testing Offers to Diagnostic Regimens for Urogenital Infections at AUA 2022

Five studies using MicroGenDX molecular testing highlight diagnostic applications, as published in May Journal of Urology
April 21, 2022

MicroGenDX Acquires Captigen and its Flatswab Inventory

MicroGenDX continues to expand its growth and expertise in molecular diagnostics by acquiring sampling innovator Captigen along with Captigen’s extensive inventory of flatswabs. The Captigen flatswab is a cross-platform precision microbial sampling device designed for optimized culture yield, RT-PCR yield, and next-generation sequencing (NGS).
February 22, 2022

MicroGenDX Licensed to Provide Clinical Diagnostic Testing in All 50 U.S. States

The New York permit approval process has required compliance with rigorous operating and proficiency standards for bacteriology and mycology laboratories. The permit became effective February 17, 2022.